Industry Skeptical Of User Fee Success, PricewaterhouseCoopers Finds
Executive Summary
FDA may be wondering whether a lack of praise for its user fee program actually could be a criticism after a survey did not find overwhelmingly agreement the dollars were serving their intended purpose.
You may also be interested in...
Economic Value Of Drugs Should Be Factor In FDA Approval, More Pharma Execs Say
PwC Health Research Institute’s survey of 100 senior executives found 43% support FDA use of economic data in deciding whether to approve a drug, up from 14% four years ago.
FDA Opens De-Regulation Docket To Collect Ideas For Repealing, Modifying Deficient Rules
House oversight committee hears plea for more transparent, predictable regulatory processes at FDA.
Few, But Fast And On Time: 2010 Saw Low NME Count, But Almost All Were First-Cycle Approvals And FDA Met Most User Fees
The rate of first-cycle approvals of new molecular entities in 2010 eclipsed previous highs, suggesting that the regulatory innovations of the FDA Amendments Act are paying off in terms of review efficiency.